Good news flowed in at
) from Europe when the European Union (EU) approved Vimpat
(lacosamide) as a single loading dose option for treating
patients suffering from partial onset seizures. Vimpat will be
used for initiation as a single loading dose (200 mg). This will
be followed by a 100 mg twice daily Vimpat maintenance dose
regimen 12 hours later.
Vimpat was first launched in the EU in Sep 2008, as an adjunctive
therapy for treating adults and and adolescents (16-18 years)
suffering from partial-onset seizures (with or without secondary
generalization) with epilepsy. We note that Vimpat revenues for
the nine months ending Sep 30, 2012 were € 237 million. UCB is
scheduled to release 2012 financial results on Feb 27, 2013.
In Dec 2012, UCB announced research data evaluating the safety
and efficacy of Vimpat in adults with partial-onset seizures
(POS) and in other special populations. A study was done on the
antiepileptic drug's (AED) safety as adjunctive therapy for
patients with primary generalized tonic-clonic seizures (PGTCS).
UCB's other major products include Cimzia, Neupro and Keppra. In
Dec 2012, UCB received the Japanese approval for Neupro and
Cimzia for Parkinson's disease and restless legs syndrome, and
for rheumatoid arthritis respectively. UCB expects combined sales
of Cimzia, Vimpat and Neupro to reach at least €3.1 billion in
the second half of this decade.
UCB carries a Zacks Rank #3 (Hold). Pharma stocks which
currently look more attractive include
Valeant Pharmaceuticals International, Inc.
Salix Pharmaceuticals Ltd.
). All three companies carry a Zacks Rank #1 (Strong Buy).
SALIX PHARM-LTD (SLXP): Free Stock Analysis
TARGACEPT INC (TRGT): Free Stock Analysis
(UCBJF): ETF Research Reports
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.